NDAINJECTIONINJECTABLE
Approved
Nov 1946
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
METHERGINE (methylergonovine maleate) by Teva is clinical pharmacology methergine (methylergonovine maleate) acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. First approved in 1946.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Methergine (methylergonovine maleate) is an ergot alkaloid that acts directly on uterine smooth muscle to increase tone, rate, and amplitude of contractions. It is indicated for prevention and treatment of postpartum hemorrhage by inducing rapid, sustained uterotonic effects during the third stage of labor. The drug has immediate onset via IV administration and 2-5 minute onset via IM injection.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling consolidation of commercial teams and shift toward defensive positioning.
Mechanism of Action
CLINICAL PHARMACOLOGY Methergine (methylergonovine maleate) acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces…
Worked on METHERGINE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.